This retrospective nationwide analysis used the Netherlands Cancer Registry to identify adults diagnosed with synchronous metastatic solid cancer from 2008 through 2022. The study covered 22 cancer types and included a total cohort of 280,419 patients. The investigators evaluated real-world patterns of systemic therapy use and population-level survival during a period when new therapies changed treatment guidelines.
Median overall survival (OS) for the full cohort improved modestly across diagnostic periods. Specifically, median OS increased from 6 months during 2008–2012 to 8 months in 2018–2022. The analysis reports this population-level change as a general improvement in survival over time but characterizes the gain as limited in magnitude when viewed across all synchronous metastatic solid cancers combined.
For the subset of patients diagnosed in 2018–2022, the study quantified real-world systemic therapy use across any line of treatment. Treatment distribution in this period was:
These proportions describe utilization patterns in routine practice during the most recent diagnostic period studied and reflect heterogeneous adoption of newer agents alongside continued use of conventional treatments or no systemic treatment at all.
The investigators report marked heterogeneity in survival outcomes across cancer types and treatment categories. Examples highlighted in the source data include:
Immunotherapy in melanoma: a treated group with a reported median survival (p50) of 67 months, illustrating a substantial subset of long-term survivors in that combination of cancer and treatment.
Targeted therapy in non–small cell lung cancer (NSCLC): a reported median survival (p50) of 22 months, with a smaller subset of patients showing notably better outcomes at lower percentiles (p10 reported as 96 months), indicating that relatively few patients experienced very long survival while the median remained more modest.
The study emphasizes that within-group percentiles (for example p10, p25, p50) reveal survival patterns that median OS alone does not capture; some treated groups contain subsets with much longer survival than the group median.
Survival percentiles within treatment and cancer types for the 2018–2022 diagnostic cohort were estimated using Kaplan–Meier analyses. Median OS was assessed by five-year diagnostic periods to illustrate temporal trends. The manuscript frames these methods as descriptive, using registry data to portray real-world outcomes rather than results from prospective randomized trials.
The authors interpret the findings as showing only modest population-level survival improvement for synchronous metastatic solid cancers between the early era of 2008–2012 and 2018–2022, despite the introduction of new systemic agents. They note the following implications:
The heterogeneity in survival within treatment and cancer types underscores both the potential benefits and the uncertainty associated with novel systemic agents in routine clinical practice.
Because survival outcomes vary substantially within treated groups, reliance on median OS alone may obscure clinically meaningful variation. Presenting multiple survival scenarios (for example, percentiles beyond the median) can better inform clinicians and patients when discussing prognosis.
Improved methods to predict individual treatment benefit are needed to reduce uncertainty and to guide treatment selection and communication about expected outcomes.
The Privacy review board of the Netherlands Comprehensive Cancer Organisation waived ethical approval for this work (reference number K23.301). The study used pseudonymised and aggregated registry data and, according to Dutch legislation, did not require approval from a medical ethics review committee. The authors declared no competing interests.
This report is a clinical preprint and has not been peer reviewed; the source notes that the findings should not yet be used to guide clinical practice. The manuscript does not provide additional trial-level details or external validation beyond the registry analyses reported.